Yahoo
NasdaqGS - Delayed Quote USD

Twist Bioscience Corporation (TWST)

124.72 -3.99 (-3.10%)
At close: September 4 at 4:00:00 PM EDT
125.40 +0.68 (+0.55%)
After hours: September 4 at 7:30:52 PM EDT
Trade TWST on Coinbase
Chart Range Bar
Loading chart for TWST
  • Previous Close 128.71
  • Open 125.19
  • Bid 91.92 x 200
  • Ask 159.59 x 200
  • Day's Range 123.75 - 128.12
  • 52 Week Range 23.30 - 155.44
  • Volume 900,733
  • Avg. Volume 1,765,823
  • Market Cap (intraday) 8.211B
  • Beta (5Y Monthly) 2.22
  • PE Ratio (TTM) --
  • EPS (TTM) -2.23
  • Earnings Date (est.) Nov 16, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 108.60

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

www.twistbioscience.com

979

Full Time Employees

September 30

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

TWST
293.19%
S&P 500 (^GSPC)
12.75%

1-Year Return

TWST
386.62%
S&P 500 (^GSPC)
18.71%

3-Year Return

TWST
429.37%
S&P 500 (^GSPC)
70.93%

5-Year Return

TWST
8.73%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 118.38M
Earnings -35.05M
Profit Margin -29.61%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
50M
100M
-38.0%
-36.0%
-34.0%
-32.0%
-30.0%
-28.0%

Analyst Insights

View More

Analyst Price Targets

36.00 Low
108.60 Average
124.72 Current
148.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/5/2026
Analyst Piper Sandler
Rating Action Maintains
Rating Overweight
Price Action Raises
Price Target 85 -> 115

Statistics

View More

Valuation Measures

Annual
As of 9/3/2026
  • Market Cap

    8.47B

  • Enterprise Value

    8.39B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    18.19

  • Price/Book (mrq)

    19.00

  • Enterprise Value/Revenue

    19.44

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -31.66%

  • Return on Assets (ttm)

    -13.09%

  • Return on Equity (ttm)

    -29.59%

  • Revenue (ttm)

    431.8M

  • Net Income Avi to Common (ttm)

    -136.72M

  • Diluted EPS (ttm)

    -2.23

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    166.84M

  • Total Debt/Equity (mrq)

    24.36%

  • Levered Free Cash Flow (ttm)

    -64.82M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

124.72 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: